Disease characteristics, comorbidities, treatment patterns and quality of life impact in children <12 years old with atopic dermatitis: Interim results from the PEDISTAD Real-World Registry - 14/10/22
Funding sources: This research was sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. |
|
IRB approval status: This study is being conducted in accordance with the principles established by the 18th World Medical Assembly and all subsequent amendments and in accordance with the guidelines for Good Epidemiology Practice. Each participating country has ensured that all the necessary local regulations are met. Ethics approval from an Institutional Review Board/Institutional Ethics Committee has been obtained in all countries currently participating in PEDISTAD. |
|
Keywords: atopic dermatitis; children; disease burden; family impact; quality of life; real-world. |
|
Reprints not available from the authors. |
Vol 87 - N° 5
P. 1104-1108 - novembre 2022 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?